Failed Allergan Deal Strains Valeant’s Business Model by JESSE EISINGER

By JESSE EISINGER

Valeant Pharmaceuticals has relied on acquisitions for growth, but it’s not so simple to keep buying and integrating companies, writes Jesse Eisinger in The Trade column.

Published: November 26, 2014 at 12:00AM

from NYT Business Day http://ift.tt/1FshuXC

from WordPress http://ift.tt/1vjNnPC

via Hadi Aboukhater